These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 8815693)
1. Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine. Kilby JM; Saag MS Adv Exp Med Biol; 1996; 394():291-8. PubMed ID: 8815693 [No Abstract] [Full Text] [Related]
2. [Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase]. de Clercq E; Snoeck R Pathol Biol (Paris); 1993 Mar; 41(3):230-6. PubMed ID: 7687340 [No Abstract] [Full Text] [Related]
3. The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors. Emini EA; Byrnes VW; Condra JH; Schleif WA; Sardana VV Arch Virol Suppl; 1994; 9():11-7. PubMed ID: 7518271 [TBL] [Abstract][Full Text] [Related]
4. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T). Balzarini J; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; Bathurst IC; Barr PJ; De Clercq E J Biol Chem; 1992 Jun; 267(17):11831-8. PubMed ID: 1376314 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s. Fan N; Rank KB; Evans DB; Thomas RC; Tarpley WG; Sharma SK FEBS Lett; 1995 Aug; 370(1-2):59-62. PubMed ID: 7544302 [TBL] [Abstract][Full Text] [Related]
6. A novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. Merluzzi VJ; Rosenthal AS Adv Exp Med Biol; 1992; 312():89-94. PubMed ID: 1381140 [No Abstract] [Full Text] [Related]
7. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. Sardana VV; Emini EA; Gotlib L; Graham DJ; Lineberger DW; Long WJ; Schlabach AJ; Wolfgang JA; Condra JH J Biol Chem; 1992 Sep; 267(25):17526-30. PubMed ID: 1381350 [TBL] [Abstract][Full Text] [Related]
8. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109 [TBL] [Abstract][Full Text] [Related]
9. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. Dollé V; Fan E; Nguyen CH; Aubertin AM; Kirn A; Andreola ML; Jamieson G; Tarrago-Litvak L; Bisagni E J Med Chem; 1995 Nov; 38(23):4679-86. PubMed ID: 7473595 [TBL] [Abstract][Full Text] [Related]
10. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. Saag MS; Emini EA; Laskin OL; Douglas J; Lapidus WI; Schleif WA; Whitley RJ; Hildebrand C; Byrnes VW; Kappes JC N Engl J Med; 1993 Oct; 329(15):1065-72. PubMed ID: 7690462 [TBL] [Abstract][Full Text] [Related]
11. Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu-138-->Arg and Tyr-188-->His mutations. Zhang H; Vrang L; Bäckbro K; Unge T; Noréen R; Oberg B Antiviral Res; 1994 May; 24(1):43-57. PubMed ID: 7524439 [TBL] [Abstract][Full Text] [Related]
12. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Kleim JP; Bender R; Kirsch R; Meichsner C; Paessens A; Riess G Virology; 1994 May; 200(2):696-701. PubMed ID: 7513921 [TBL] [Abstract][Full Text] [Related]
13. [Non-nucleoside inhibitors of reverse transcriptase in therapy of HIV-infection]. Galegov GA Antibiot Khimioter; 2005; 50(4):23-6. PubMed ID: 16392336 [No Abstract] [Full Text] [Related]
14. Quantitative analysis of the endogenous reverse transcriptase reactions of HIV type 1 variants with decreased susceptibility to azidothymidine and nevirapine. Krogstad P; Chen IS; Canon J; Rey O AIDS Res Hum Retroviruses; 1996 Jul; 12(11):977-83. PubMed ID: 8827213 [TBL] [Abstract][Full Text] [Related]
15. New type of HIV drug. Treat Rev; 1995 Nov; (no 20):4. PubMed ID: 11363022 [TBL] [Abstract][Full Text] [Related]
16. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Condra JH; Emini EA; Gotlib L; Graham DJ; Schlabach AJ; Wolfgang JA; Colonno RJ; Sardana VV Antimicrob Agents Chemother; 1992 Jul; 36(7):1441-6. PubMed ID: 1380789 [TBL] [Abstract][Full Text] [Related]
17. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778 [TBL] [Abstract][Full Text] [Related]
18. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Spence RA; Kati WM; Anderson KS; Johnson KA Science; 1995 Feb; 267(5200):988-93. PubMed ID: 7532321 [TBL] [Abstract][Full Text] [Related]